Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 45,996 Shares of Stock

Key Points

• Director Edward Md Kaye sold 45,996 shares of Stoke Therapeutics at an average price of $20.13, resulting in a total transaction of approximately $925,899.48.
• Stoke Therapeutics reported a quarterly earnings per share (EPS) of ($0.40), exceeding analyst expectations by $0.17, despite revenue falling short of estimates at $13.82 million.
• Several institutional investors have significantly increased their stakes in Stoke Therapeutics, notably Tower Research Capital raising its position by 461.0% in the second quarter.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Edward M. Md Kaye sold 45,996 shares of Stoke Therapeutics stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $20.13, for a total value of $925,899.48. Following the completion of the transaction, the director directly owned 91,585 shares in the company, valued at $1,843,606.05. This represents a 33.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Stoke Therapeutics Price Performance

NASDAQ STOK traded up $1.05 during mid-day trading on Friday, hitting $20.68. The company's stock had a trading volume of 542,954 shares, compared to its average volume of 999,282. The firm has a market capitalization of $1.13 billion, a P/E ratio of 24.33 and a beta of 1.14. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $20.90. The stock's fifty day simple moving average is $14.92 and its two-hundred day simple moving average is $11.06.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The company had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. On average, equities analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

STOK has been the subject of a number of recent research reports. HC Wainwright lowered their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Wedbush increased their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research report on Wednesday, August 13th. BTIG Research set a $28.00 price objective on shares of Stoke Therapeutics and gave the company a "buy" rating in a research note on Monday, August 18th. Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Finally, Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Two investment analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $25.57.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors have recently modified their holdings of the stock. Toronto Dominion Bank bought a new stake in Stoke Therapeutics in the fourth quarter valued at about $35,001,000. Corient Private Wealth LLC bought a new position in Stoke Therapeutics during the 2nd quarter worth approximately $7,489,000. RTW Investments LP grew its position in shares of Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock worth $56,512,000 after acquiring an additional 471,240 shares in the last quarter. Checkpoint Capital L.P. increased its holdings in shares of Stoke Therapeutics by 139.3% in the 1st quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company's stock valued at $4,859,000 after acquiring an additional 425,330 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new stake in shares of Stoke Therapeutics in the 1st quarter valued at approximately $2,670,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.